论文部分内容阅读
[目的]评价康复新液对胆汁反流性胃炎的治疗效果。[方法]将胃镜下诊断胆汁反流性胃炎的186例患者随机分为2组,对照组给予铝碳酸镁1.0g,每天3次,莫沙必利5mg,每天3次口服治疗,而治疗组在此基础上加用康复新液10ml,每天3次口服,8周后观察两组临床症状缓解情况、胃镜下炎症修复情况及病理结果。[结果]治疗后两组临床症状均明显改善,但治疗组同对照组比较差异无显著性(P>0.05);治疗后两组胃镜下炎症修复均明显改善,治疗组同对照组比较差异有统计学意义(P<0.05)。治疗组中肠化、萎缩及不典型增生的检出率均低于对照组(P<0.05)。治疗组总有效率94.8%,对照组80.4%,2组治疗有效率差异有统计学意义(P<0.05)。[结论]康复新液在治疗胆汁反流性胃炎中有较好疗效。
[Objective] To evaluate the therapeutic effect of Kangfuxin solution on bile reflux gastritis. [Methods] 186 patients diagnosed bile reflux gastritis under endoscopy were randomly divided into two groups. The control group was given 1.0 g magnesium aluminum carbonate 3 times a day, mosapride 5 mg orally 3 times a day, while the treatment group On this basis, 10ml Kangfuxin solution was added and taken orally 3 times a day. After 8 weeks, the relief of clinical symptoms, inflammation repair under endoscopy and pathological results were observed. [Results] The clinical symptoms of both groups were significantly improved after treatment, but there was no significant difference between the treatment group and the control group (P> 0.05). After the treatment, the inflammation repaired by gastroscopy was significantly improved in both groups, and there was significant difference between the treatment group and the control group Statistical significance (P <0.05). The detection rate of intestinal metaplasia, atrophy and dysplasia in the treatment group was lower than that in the control group (P <0.05). The total effective rate was 94.8% in the treatment group and 80.4% in the control group, and the difference was statistically significant (P <0.05). [Conclusion] Kangfuxin solution has good curative effect in the treatment of bile reflux gastritis.